A phase Ib/II trial (NCT04234061) is evaluating epcoritamab in combination with the BTK inhibitor ibrutinib in patients with R/R mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.